With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1206487-35-5,4,6-Dibromopyridazin-3-amine,as a common compound, the synthetic route is as follows.
To a stirred solution of 4-bromo-6-bromopyridazin-3-amine (3a), (0.20 g, 0.79 mmol) in DML (5 mL) were ethyl 2-(3,8-diazabicyclo[3.2.1]octan-8-yl)acetate hydrochloride (0.278 g, 1.11 mmol ) and DIPEA (0.7 mL, 3.95 mmol) at RT and stirred for 16 h at 90 C under nitrogen atmosphere. Then the reaction mixture was quenched with cold water (20 mL) and the brown solid obtained was washed with diethyl ether, filtered and dried under vacuum. The same procedure was repeated four times to afford pure title compound (0.155 g, Yield : 55 %). 1H NMR (400 MHz, DMSO-d6): d 6.96 (s, 1H), 5.76 (s, 2H), 4.15-4.03 (m, 2H), 3.37-3.29 (m, 2H), 3.19 (s, 2H), 3.16-3.14 (m, 2H), 2.83-2.80 (m, 2H), 1.85 (s, 4H), 1.23-1.13 (m, 3H); LC-MS: m/z 371.1 (M+l)+., 1206487-35-5
Big data shows that 1206487-35-5 is playing an increasingly important role.
Reference£º
Patent; AURIGENE DISCOVERY TECHNOLOGIES LIMITED; SASMAL, Sanjita; SAMAJDAR, Susanta; MUKHERJEE, Subhendu; ABBINENI, Chandrasekhar; (260 pag.)WO2019/207538; (2019); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem